Skip to content
Medical Health Aged Care, Women

Landmark gathering to hear of promising uptake on cervical cancer screening

Public Health Association of Australia 2 mins read

Media alert

1 August 2023

Preliminary results from one of Australia’s largest randomised controlled trials suggest that HPV-based screening used in the National Cervical Cancer Screening Program is more effective at detecting pre-cancerous changes than the Pap Smear program it replaced.

If the early results from the Compass Trial are confirmed when it concludes in 2026, this would allow more women and people with a cervix to be treated before these changes develop into cervical cancer, alleviating for many people the trauma of a cancer diagnosis, and ultimately saving more lives.

The update, from the Australian Centre for the Prevention of Cervical Cancer and the Daffodil Centre, will be shared with 150 Australian and international screening experts, researchers, and policymakers today in Melbourne at Cancer Screening: Evidence, challenges and solutions, organised by the Public Health Association of Australia (PHAA). Sessions will cover cancers including lung, breast, and melanoma and skin cancer.

The cancer screening symposium is the first of its kind to be convened on the continent. Delegates will discuss the latest evidence and initiatives to promote early cancer detection, and whether there is evidence to support changes to screening programs, or the introduction of new screening technologies.

The symposium’s international keynote speaker is Prof Bob Steele CBE, who led the United Kingdom’s demonstration pilot that was used to inform the decision to introduce national bowel cancer screening programmes throughout the UK. The Professor of Surgery at the University of Dundee is the Clinical Director of the Scottish Bowel Cancer Screening Programme. Prof Steele was also the Chair of UK National Screening Committee for six years until 2022, and has significant expertise in screening evidence, emerging screening technologies, and the latest proposals.

The event agenda includes discussions on: 

  • Cancer screening – where to next in Australia and the UK?
  • When equity is the goal – initiatives to ensure screening programs activity address outcome disparities 
  • Building timely evidence for screening program changes and new technologies
  • “Are we ready for the future?”

Media are invited to attend online or in-person, and request interviews with presenters.

 

WHO: Public Health Association of Australia

WHAT: Screening Symposium. Cancer Screening: Evidence, challenges, and solutions

WHERE: Melbourne Convention Exhibition Centre, (Clarendon Foyer and Auditorium)

WHEN: 9am – 5:15pm, Tuesday 1 August 2023

 

For further information/comment:

Paris Lord (he/him), PHAA Communications and Media Manager, M) 0478 587 917 / [email protected]

A/Prof Misha Coleman, Government Relations and Communications Director,
Australian Centre for the Prevention of Cervical Cancer, M) 0428 399 739,
[email protected]


Contact details:

Paris Lord (he/him), PHAA Communications and Media Manager, M) 0478 587 917 / [email protected]

A/Prof Misha Coleman, Government Relations and Communications Director,
Australian Centre for the Prevention of Cervical Cancer, M) 0428 399 739,
[email protected]

Media

More from this category

  • Medical Health Aged Care
  • 18/12/2025
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma

BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancer FDA Fast Track Designation reflects the…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 19:11
Takeda Pharmaceutical Company Limited

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half…

  • Contains:
  • Medical Health Aged Care
  • 18/12/2025
  • 12:24
La Trobe University

Cell death discovery could aid cancer treatments

LaTrobe researchers have made a groundbreaking discovery about the way dying cells are cleared from our bodies, which could have important impacts on recovery from diseases including cancer infection and inflammatory diseases. Traditionally, it was believed dying cells were broken into smaller pieces by the cell’s own internal machinery, enabling the pieces to be more easily removed from the body. However the study, led by scientists at the La Trobe Institute for Molecular Science and Research Centre for Extracellular Vesicles found that the process of dying cell fragmentation is actually assisted by neighbouring cells. Published in Science Advances, the study…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.